Clinical Trial Update: Duration of Anti-PD-1 Therapy in Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update examining the optimal duration of anti-PD-1 therapy for unresectable/metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Unresectable/Metastatic Melanoma | Phase 3 | Status: RECRUITING